Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DexCom, Inc. (DXCM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K, and quarterly reports on Form 10-Q when filed. Dexcom is listed on the Nasdaq Stock Market under the symbol DXCM, and its SEC filings offer detailed information on financial performance, governance, and material events related to its glucose biosensing and continuous glucose monitoring (CGM) business.
Recent Form 8-K filings illustrate how Dexcom uses SEC reports to communicate key developments. For example, the company has filed 8-Ks to furnish quarterly financial results, including revenue by geography and product component, and to describe leadership transitions such as the appointment of Jacob S. Leach as President and Chief Executive Officer and the appointment of Dr. Euan Ashley to the Board of Directors. These filings also document changes in board size, committee assignments, and executive roles.
Dexcom’s periodic reports, including 10-K and 10-Q filings when available, typically contain audited financial statements, discussions of sensor and hardware revenue, descriptions of its CGM and biosensing operations, and risk factor disclosures. Investors can also review sections on research and development spending, capital structure, and non-GAAP performance metrics that the company discusses alongside GAAP results in its earnings-related 8-Ks.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand revenue trends, margin commentary, governance updates, and other material items. Users can also monitor items related to director and executive appointments or departures, and other reportable events under Form 8-K. This page is a central resource for analyzing Dexcom’s regulatory history and for tracking how financial and governance information evolves over time.
Dexcom Inc Schedule 13G filer Vanguard Capital Management reports beneficial ownership of 28,848,218 shares of Common Stock, representing 7.49% of the class as of 03/31/2026. The filing states sole dispositive power over 28,848,218 shares and sole voting power over 3,827,257 shares.
The filing notes ownership includes securities held by Vanguard funds and certain affiliates exercising dispositive or voting power per SEC Release No. 34-39538. The reporting person is Vanguard Capital Management; transactions or changes after the reported date are not included in this excerpt.
Dexcom Inc ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 19,322,566 shares of Common Stock, representing 5.02% of the class as of 03/31/2026. The filing shows sole dispositive power over 19,322,566 shares and sole voting power of 102,613 shares. The disclosure states ownership includes securities held by Vanguard funds and certain affiliates and is signed on 04/29/2026 by Ashley Grim.
Dexcom Inc.’s EVP and Chief Legal Officer Michael Jon Brown sold 1,700 shares of common stock in an open-market transaction. The shares were sold at $63.04 each under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025.
Following this sale, Brown directly owns 111,204 Dexcom shares77,603 unvested RSUs, with grants made on March 8, 2026, March 8, 2025, and March 8, 2024 that are scheduled to vest through March 8, 2029.
DexCom, Inc. is asking stockholders to elect twelve directors, ratify Deloitte & Touche LLP as auditor for 2026, and approve 2025 executive pay on an advisory basis. The company highlights strong 2025 performance, including $4.66 billion in revenue (up 16% from 2024) and $836.3 million in net income (up 45%).
Operating income reached $911.8 million and operating cash flow was $1.44 billion, ending 2025 with $2.00 billion in cash, cash equivalents and short-term marketable securities. Dexcom also repurchased $500.0 million of stock under a $750.0 million authorization and expanded its customer base to about 3.5 million global users.
The proxy details a refreshed, mostly independent Board, including new directors with medical, pharmaceutical and technology backgrounds, a lead independent director structure, comprehensive committee oversight (audit, compensation, nominating and governance, and technology), an insider trading and clawback policy, and a pay program emphasizing equity-based compensation and stock ownership guidelines for directors and executives.
Michael Brown submitted a Form 144 notice indicating an intended sale of 1,700 shares of Common Stock originally acquired as restricted stock. The filing shows transaction dates of 03/08/2026 (acquisition) and 03/16/2026 (sale activity), with the filing recorded on 04/15/2026.
Dexcom Inc ownership filing: The Vanguard Group filed an amendment stating it beneficially owns 0 shares of Dexcom common stock, representing 0% of the class. The amendment explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, where certain Vanguard subsidiaries will report disaggregated beneficial ownership.
Dexcom Inc. executive Michael Jon Brown, EVP and Chief Legal Officer, reported an open-market sale of 1,700 shares of common stock at $64.85 per share. The transaction occurred on March 16, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025.
After this sale, Brown directly holds 112,904 Dexcom shares. This figure includes 77,603 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029, reflecting a substantial continuing equity stake aligned with the company’s long-term performance.
DexCom Inc. Executive Chair Kevin R. Sayer reported routine equity compensation activity. He received a grant of 32,749 restricted stock units (RSUs) of DexCom common stock on March 8, 2026. These RSUs are scheduled to vest on the one-year anniversary of the grant date.
The filing also shows 32,498 shares of common stock withheld by DexCom at $68.10 per share to satisfy tax withholding and remittance obligations related to RSU settlement, which the company states does not represent a sale by Sayer. After these transactions, he directly holds 409,241 shares, including 106,972 unvested RSUs with various vesting schedules through March 8, 2028.